Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients.
Docetaxel (Doc)
non-small cell lung cancer (NSCLC)
programmed death-ligand 1
ramucirumab (Ram)
retrospective study
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
entrez:
27
9
2019
pubmed:
27
9
2019
medline:
27
9
2019
Statut:
ppublish
Résumé
Current clinical trials demonstrated that combination regimens comprising chemotherapy and immunotherapy lead to better patient outcomes compared to chemotherapy alone as the first line of treatment for non-small cell lung cancer (NSCLC). In addition, the combination therapy of docetaxel (Doc) and ramucirumab (Ram) was considered one of the standard treatments for advanced or relapsed NSCLC patients. However, little is known about the therapeutic responders of this combination therapy among previously treated NSCLC patients. In the present study, we aimed to identify predictive factors for therapeutic response, including programmed death-ligand 1 (PD-L1) expression in tumors, for Doc treatment in combination with Ram. We retrospectively analyzed a total of 135 advanced or relapsed NSCLC patients who were refractory to platinum-based chemotherapy at eleven institutions in Japan between July 2016 and November 2018. Our observations showed that PD-L1 expression in tumors is not associated with the efficacy of combined therapy of Doc and Ram in previously treated NSCLC patients. Analysis of the patient clinical profiles indicated that prior treatment with immune checkpoint inhibitors (ICIs) is a reliable predictor for the good progression-free survival (PFS) to this combination therapy (P=0.041). Our retrospective study indicated that combination regimens comprising chemotherapy and ICIs followed by Doc and Ram could be an optimal therapeutic option for NSCLC patients regardless of the PD-L1 status of tumors. Further investigations are required to strengthen clinical evidence demonstrating the effectiveness of the combination therapy of Doc plus Ram in previously treated NSCLC patients.
Sections du résumé
BACKGROUND
BACKGROUND
Current clinical trials demonstrated that combination regimens comprising chemotherapy and immunotherapy lead to better patient outcomes compared to chemotherapy alone as the first line of treatment for non-small cell lung cancer (NSCLC). In addition, the combination therapy of docetaxel (Doc) and ramucirumab (Ram) was considered one of the standard treatments for advanced or relapsed NSCLC patients. However, little is known about the therapeutic responders of this combination therapy among previously treated NSCLC patients. In the present study, we aimed to identify predictive factors for therapeutic response, including programmed death-ligand 1 (PD-L1) expression in tumors, for Doc treatment in combination with Ram.
METHODS
METHODS
We retrospectively analyzed a total of 135 advanced or relapsed NSCLC patients who were refractory to platinum-based chemotherapy at eleven institutions in Japan between July 2016 and November 2018.
RESULTS
RESULTS
Our observations showed that PD-L1 expression in tumors is not associated with the efficacy of combined therapy of Doc and Ram in previously treated NSCLC patients. Analysis of the patient clinical profiles indicated that prior treatment with immune checkpoint inhibitors (ICIs) is a reliable predictor for the good progression-free survival (PFS) to this combination therapy (P=0.041).
CONCLUSIONS
CONCLUSIONS
Our retrospective study indicated that combination regimens comprising chemotherapy and ICIs followed by Doc and Ram could be an optimal therapeutic option for NSCLC patients regardless of the PD-L1 status of tumors. Further investigations are required to strengthen clinical evidence demonstrating the effectiveness of the combination therapy of Doc plus Ram in previously treated NSCLC patients.
Identifiants
pubmed: 31555518
doi: 10.21037/tlcr.2019.08.07
pii: tlcr-08-04-450
pmc: PMC6749132
doi:
Types de publication
Journal Article
Langues
eng
Pagination
450-460Déclaration de conflit d'intérêts
Conflicts of Interest: Dr. Yamada reports receiving research grants from Pfizer Inc., Boehringer Ingelheim Japan Inc., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd., and Chugai Pharmaceutical Co., Ltd. Dr. Uchino reports receiving research grants from Eli Lilly Japan K.K., AstraZeneca K.K., and Boehringer Ingelheim Japan Inc. Dr. Takayama reports receiving research grants from Chugai-Roche Co., and Ono Pharmaceutical Co., and personal fees from AstraZeneca Co., Chugai-Roche Co., MSD-Merck Co., Eli Lilly Co., Boehringer-Ingelheim Co., and Daiichi-Sankyo Co. The other authors have no conflicts of interest to declare.
Références
J Clin Oncol. 2006 Oct 1;24(28):4539-44
pubmed: 17008692
J Clin Oncol. 2010 Feb 10;28(5):780-7
pubmed: 20048182
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Cancer. 2011 May 15;117(10):2192-201
pubmed: 21523733
Clin Cancer Res. 2012 Apr 1;18(7):1925-35
pubmed: 22322668
Chin Med J (Engl). 2012 Jun;125(11):2004-11
pubmed: 22884069
BMC Gastroenterol. 2012 Aug 16;12:109
pubmed: 22894700
Korean J Pathol. 2013 Oct;47(5):443-51
pubmed: 24255632
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
Lancet. 2014 Aug 23;384(9944):665-73
pubmed: 24933332
Ann Oncol. 2014 Nov;25(11):2178-84
pubmed: 25193987
Lung Cancer. 2015 Feb;87(2):193-200
pubmed: 25564398
Clin Cancer Res. 2015 Oct 1;21(19):4286-93
pubmed: 25977344
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
J Cancer. 2017 Jul 5;8(11):2018-2025
pubmed: 28819402
Int J Cancer. 2018 Mar 15;142(6):1277-1284
pubmed: 29080213
Lung Cancer. 2018 Jan;115:12-20
pubmed: 29290252
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
CA Cancer J Clin. 2018 Nov;68(6):425-445
pubmed: 30285281
J Immunother Cancer. 2018 Oct 11;6(1):106
pubmed: 30314524
Thorac Cancer. 2019 Apr;10(4):775-781
pubmed: 30809973